Market closed
Omeros/$OMER
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Omeros
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Ticker
$OMER
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
202
Website
Omeros Metrics
BasicAdvanced
$424M
-
-$2.70
2.35
-
Price and volume
Market cap
$424M
Beta
2.35
52-week high
$13.60
52-week low
$2.97
Average daily volume
765K
Financial strength
Current ratio
1.686
Quick ratio
1.231
Long term debt to equity
-205.719
Total debt to equity
-231.794
Interest coverage (TTM)
-6.86%
Management effectiveness
Return on assets (TTM)
-32.28%
Return on equity (TTM)
175.95%
Valuation
Price to book
-2.32
Price to tangible book (TTM)
-2.32
Price to free cash flow (TTM)
-2.851
Growth
Earnings per share change (TTM)
43.56%
3-year earnings per share growth (CAGR)
-4.71%
What the Analysts think about Omeros
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Omeros stock.
Omeros Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Omeros Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Omeros News
AllArticlesVideos
Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight
Benzinga·2 weeks ago
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program
Business Wire·2 weeks ago
Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript
Seeking Alpha·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Omeros stock?
Omeros (OMER) has a market cap of $424M as of April 25, 2025.
What is the P/E ratio for Omeros stock?
The price to earnings (P/E) ratio for Omeros (OMER) stock is 0 as of April 25, 2025.
Does Omeros stock pay dividends?
No, Omeros (OMER) stock does not pay dividends to its shareholders as of April 25, 2025.
When is the next Omeros dividend payment date?
Omeros (OMER) stock does not pay dividends to its shareholders.
What is the beta indicator for Omeros?
Omeros (OMER) has a beta rating of 2.35. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.